Committee declines to advance bill requiring COVID‑vaccine disclosure and labeling on donated blood after expert testimony

The Idaho Senate Health and Welfare Committee heard several hours of testimony on House Bill 131, which would require collection of a donor's disclosure about mRNA COVID‑19 vaccination and permit nonemergency patients to request blood labeled with that disclosure. After testimony from hospitals, blood centers, transfusion specialists and the Red Cross, the committee voted not to advance the bill.

Representative Bruce, sponsor, said the bill would add a donor-question disclosure about COVID‑19 mRNA vaccination, allow units to be labeled accordingly and let nonemergency recipients request labeled blood when available. He characterized the proposal as an informed‑consent and patient‑choice measure and said it did not challenge vaccine safety.

Witnesses opposing the bill said it could not be implemented and would risk Idaho's blood supply. Nicole Erwin, CEO of the American Red Cross of Idaho, said the Red Cross collects and distributes tens of thousands of units a year in the state and that "it's impossible to implement this law," adding that there is no laboratory test to verify whether a donor received an mRNA vaccine and that labeling based on unverified self‑report would be misleading and could endanger the supply. Vitalant's regional director, Michael Martinez, and other witnesses said separating donations by self‑reported vaccination status would complicate inventory management, increase costs and could deter donors.

Medical experts and blood‑bank directors described the technical and regulatory constraints. Dr. Jessica Corian, a transfusion‑medicine physician, said inventory management is already challenging and that directed donations and freezing rare units require specialized processing; she warned the bill could increase waste and make units harder to locate when needed. Dr. Cole Elliott, the Red Cross medical director for Idaho, cited a recent study of more than 7,700 hospital patients that found no association between transfusions from vaccinated donors and adverse outcomes and warned that the bill could subject the medical community to litigation and accreditation risk.

Supporters who spoke said some patients want the ability to choose and that a labeled disclosure would allow informed choice for those who prefer blood from self‑identified unvaccinated donors. Representative Bruce argued state law may add requirements beyond FDA minimums and that the bill would function as a patient‑driven variant of directed donation in nonemergency situations.

After deliberation the committee took a final vote on a motion to send HB 131 to the floor with a due‑pass recommendation; the motion failed. Committee members who opposed advancement cited the inability of blood centers to verify vaccination status, the lack of an FDA‑approved test, and the potential impact on the already tight blood supply. Senator Ziederfeld made the motion to advance the bill and it was seconded; the committee ultimately rejected the motion and the bill did not advance from committee that day.

The testimony underscored a central technical constraint: witnesses and regulators cited in testimony said there is currently no validated laboratory test to detect an mRNA vaccine product in a donated unit, and federal donor‑screening and labeling rules and FDA accreditation standards constrain what blood centers can label and distribute. Witnesses urged further study before legislative changes.